Clinical trials: Disorder of the Lower Urinary Tract
Overactive Bladder
Evaluation of the The Neuromodulation System for the Treatment of Overactive Bladder Symptoms
To evaluate the efficacy and safety of non-invasive tibial nerve stimulator for the treatment of overactive bladder under the premise of ensuring the safety of the subjects and ensuring the scientific nature of the clinical…
- Trial name
- NCT04999657
- Testing
- Non-invasive low-frequency tibial nerve stimulator (TNS-01)
- Where
- 7 sites in China
- Volunteers
- 109 people
- Sponsor
- Medtecx Co Ltd.
Benign Prostatic Hyperplasia, Erectile Dysfunction
The Efficacy and Safety of the Combination of Tamsulosin and Tadalafil in Men With Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia and Erectile Dysfunction
The efficacy and safety of the combination of tamsulosin and tadalafil in men with lower urinary tract symptoms due to benign prostatic hyperplasia and Erectile Dysfunction: a randomized, double blinded, parallel design, active…
- Trial name
- NCT02862483
- Testing
- Tamsulosin 0.2mg, Tadalafil 5mg
- Where
- South Korea
- Volunteers
- 330 people
- Sponsor
- IlDong Pharmaceutical Co Ltd
Overactive Bladder With Urge Urinary Incontinence
URO-902 in Female Subjects With Overactive Bladder and Urge Urinary Incontinence
This study will evaluate the efficacy, safety, and tolerability of a single dose of URO-902 24 milligrams (mg) and 48 mg (administered via intradetrusor injection), compared with placebo, in participants with overactive bladder…
- Trial name
- NCT04211831
- Testing
- URO-902
- Where
- 20 sites in United States
- Volunteers
- 80 people
- Sponsor
- Urovant Sciences GmbH
Benign Prostatic Hyperplasia (BPH)
Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue (WATER)
A prospective multicenter randomized blinded study comparing Aquablation of the prostate with the AQUABEAM System and TURP for the treatment of Lower Urinary Tract Symptoms (LUTS).
- Trial name
- WATER (NCT02505919)
- Testing
- AQUABEAM System, Transurethral Resection of the Prostate (TURP)
- Where
- 17 sites in United States, Australia and 2 more
- Volunteers
- 184 people
- Sponsor
- PROCEPT BioRobotics
Urinary Incontinence, Urge
A Study of Oxybutynin for the Treatment of Urge Urinary Incontinence
The purpose of this study is to determine the safety of three doses of oxybutynin for the treatment of urge urinary incontinence.
- Trial name
- FP1097-002 (NCT00749632)
- Testing
- oxybutynin
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- FemmePharma Global Healthcare, Inc.
Nocturia
Efficacy Study of Fedovapagon for Nocturia in Men With Benign Prostatic Hyperplasia (BPH)
This study will investigate the efficacy and safety of fedovapagon in the treatment of nocturia in men with BPH.
- Trial name
- EQUINOC (NCT02637960)
- Testing
- Fedovapagon 2 mg
- Where
- 48 sites in United States
- Volunteers
- 432 people
- Sponsor
- Vantia Ltd
Incontinence, Urinary, Incontinence, Fecal
Testing the Protective and Caring Effect of a Water-in-oil Formulation in Patients Suffering From Urinary and/or Fecal Incontinence and Requiring Incontinence Care Products
The aim of this study is to test the protecting and caring effect of a protective balm on patients suffering from urinary and/or fecal incontinence and need incontinence care products.
- Trial name
- NCT06924502
- Testing
- Protective Balm
- Where
- Germany
- Volunteers
- 33 people
- Sponsor
- Dr. August Wolff GmbH & Co. KG Arzneimittel
Heart Failure, Overactive Bladder
Effect of Extended Release Torsemide in Patients With Congestive Heart Failure and Overactive Bladder
This research study is being done to compare the effectiveness two drugs: an Extended Release Torsemide (ERT) versus generic Immediate Release Torsemide (IRT) in reducing the worsening of symptoms of Overactive Bladder (OAB…
- Conditions
- Heart Failure, Overactive Bladder, Incontinence
- Trial name
- NCT06206512
- Testing
- Extended release torsemide, Immediate release torsemide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Sarfez Pharmaceuticals, Inc.
Urinary Incontinence, Urinary Bladder, Overactive
An Observational Study of BOTOX® for the Management of Urinary Incontinence in Patients With Idiopathic Overactive Bladder
This study will evaluate real world pattern of use of BOTOX® in actual clinical practice in patients with idiopathic overactive bladder (iOAB) with urinary incontinence whose symptoms have not been adequately managed by oral…
- Trial name
- GRACE (NCT02161159)
- Testing
- botulinum toxin Type A
- Where
- 54 sites in Germany, Spain and 2 more
- Volunteers
- 515 people
- Sponsor
- Allergan
Overactive Bladder
Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)
This study will assess the efficacy of vibegron compared with placebo in men with overactive bladder (OAB) symptoms on pharmacological therapy for benign prostatic hyperplasia (BPH) as defined by micturition and urgency episodes.
- Trial name
- NCT03902080
- Testing
- Vibegron
- Where
- 140 sites in United States, Belgium and 6 more
- Volunteers
- 1,105 people
- Sponsor
- Urovant Sciences GmbH
Urinary Incontinence, Urge
CAN-Stim Compared to SNS in Treatment of Urinary Urgency Incontinence With Wireless Neuromodulation Technology
This is a prospective, randomized, controlled, multi-center, study in which 150 evaluable subjects will be randomized 1:1 to receive either a Protect CAN-Stim or SNS InterStim® system.
- Trial name
- PROTECT (NCT02577302)
- Testing
- CAN-Stim - Protect CAN-Stim System, SNS - InterStim® System
- Where
- 15 sites in United States
- Volunteers
- 200 people
- Sponsor
- Uro Medical Corporation
Urinary Bladder, Overactive
A Study to Evaluate the Efficacy of Tolterodine on Specific Symptoms in Adult Patients With Overactive Bladder.
The purpose of this study is to evaluate the efficacy and safety of tolterodine in impacting the primary symptom or complaint of patients with OAB.
- Trial name
- NCT00645281
- Testing
- tolterodine extended release
- Where
- 96 sites in United States
- Volunteers
- 896 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Prostatic Hyperplasia
Urodynamic Effects of UK-369,003 in Men With Lower Urinary Tract Symptoms
This is a pilot study to generate hypotheses about the urodynamic effects of UK-369,003 in men with lower urinary tract symptoms.
- Trial name
- NCT00408954
- Testing
- UK-369,003
- Where
- 11 sites in Czechia, Netherlands and 1 more
- Volunteers
- 27 people
- Sponsor
- Pfizer
Benign Prostatic Hyperplasia
A Clinical Study to Evaluate the Safety and Efficacy of the FloStent in Men With Benign Prostatic Hyperplasia Symptoms
The goal of this study is to determine the safety and effectiveness of the FloStent, a medical device used to treat men with symptoms of Benign Prostatic Hyperplasia, compared to sham (procedure without deployment of the…
- Trial name
- RAPID-III (NCT06849258)
- Testing
- FloStent
- Where
- 20 sites in United States, Australia
- Volunteers
- 215 people
- Sponsor
- Rivermark Medical
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Neuflo System for the Treatment of BPH
The goal of this clinical study is to assess the effectiveness and safety of the Neuflo System for the treatment of benign prostatic hyperplasia (BPH).
- Trial name
- NCT05884580
- Testing
- Neuflo BPH Treatment System
- Where
- New Zealand
- Volunteers
- 1 people
- Sponsor
- ProstaCare Pty Ltd
Neurogenic Overactive Bladder, Urinary Incontinence
Efficacy Study of Pudendal Neuromodulation for the Treatment of Neurogenic Overactive Bladder
The study is designed to demonstrate that treatment with low level stimulation of the bladder muscles reduces symptoms of urinary incontinence in comparison with no stimulation.
- Conditions
- Neurogenic Overactive Bladder, Urinary Incontinence, Detrusor Overactivity
- Trial name
- ACCEPTANCE (NCT01023269)
- Testing
- InterStim Therapy
- Where
- 8 sites in Belgium, France and 4 more
- Volunteers
- 17 people
- Sponsor
- MedtronicNeuro
Overactive Bladder
Dose-Finding Study To Evaluate The Efficacy, Tolerability And Safety Of Fesoterodine In Comparison To Placebo For Overactive Bladder.
To evaluate the efficacy and safety of fesoterodine in comparison to placebo for overactive bladder.
- Trial name
- NCT00561951
- Testing
- fesoterodine fumarate
- Where
- 65 sites in Hong Kong, Japan and 2 more
- Volunteers
- 951 people
- Sponsor
- Pfizer
Stress Urinary Incontinence
The Nolix Feasibility Efficacy and Safety Study
This study is an open label, prospective, feasibility study with the Nolix device used for temporary treatment of Stress Urinary Incontinence (SUI) in subjects, serving as their own controls.
- Trial name
- NCT04143867
- Testing
- Nolix Device
- Where
- Israel
- Volunteers
- 32 people
- Sponsor
- Gynamics LTD
Detrusor Overactivity, Multiple Sclerosis
A Parallel Group Study to Compare Sativex® With Placebo in the Treatment of Detrusor Overactivity in Patients With Multiple Sclerosis
The purpose of this study is to evaluate the efficacy of Sativex® compared with placebo in reducing the daily number of episodes on incontinence.
- Trial name
- NCT00678795
- Testing
- Sativex®
- Where
- United Kingdom
- Volunteers
- 135 people
- Sponsor
- Jazz Pharmaceuticals
Overactive Bladder
Safety Study of hMaxi-K Gene Transfer to Treat Overactive Bladder and Detrusor Overactivity
The purpose of this study is to evaluate the safety of a new product that uses human gene transfer (called hMaxi-K) when it is given to patients with overactive bladder.
- Trial name
- NCT00495053
- Testing
- hMaxi-K
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Urovant Sciences GmbH